Madrigal Pharmaceuticals, Inc.
MDGL
$301.66
-$6.12-1.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 47.04% | -8.33% | -77.12% | -91.87% | -30.60% |
| Total Depreciation and Amortization | 155.63% | 120.74% | 111.90% | 35.48% | 10.08% |
| Total Amortization of Deferred Charges | -35.99% | -28.78% | -14.80% | 51.27% | 146.08% |
| Total Other Non-Cash Items | 19.40% | 37.76% | 122.40% | 76.91% | 83.77% |
| Change in Net Operating Assets | -485.42% | 6,100.00% | -597.94% | -17.72% | -12.50% |
| Cash from Operations | -30.72% | 21.12% | -79.19% | -77.43% | -36.60% |
| Capital Expenditure | 81.18% | -129.79% | -89.86% | -920.00% | -3,472.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.77% | -498.93% | -3,229.70% | 152.67% | -643.67% |
| Cash from Investing | 86.76% | -503.18% | -3,171.65% | 152.47% | -645.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.88% | 60.30% | 378.93% | 3,104.52% | 81.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.88% | -61.89% | 212.42% | 988.83% | 81.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -450.41% | -1,629.83% | -240.39% | 339.46% | -86.09% |